2024
Brief Report: Should a prior cancer history be reevaluated as an exclusion for clinical trial participation?
Ayoade O, Canavan M, Caturegli G, Boffa D. Brief Report: Should a prior cancer history be reevaluated as an exclusion for clinical trial participation? Lung Cancer 2024, 198: 108032. PMID: 39561624, DOI: 10.1016/j.lungcan.2024.108032.Peer-Reviewed Original ResearchNon-small cell lung cancerAssociated with superior survivalSuperior survivalStage III NSCLC patientsCancer historyIII NSCLC patientsReceipt of immunotherapyNational Cancer DatabaseRegimens of chemotherapyStage IV patientsAnalyze overall survivalCell lung cancerKaplan Meier analysisStage III andCox proportional hazards modelsProportional hazards modelInnovative treatment approachesInfluence patient outcomesNSCLC patientsIV patientsOverall survivalImmunotherapy trialsCancer DatabaseMeier analysisNon-small
2019
Benefit of combining local treatment and systemic therapy for stage IV NSCLC: Results from the National Cancer Database.
Dendy Case M, Uhlig J, Blasberg J, Boffa D, Chiang A, Gettinger S, Kim H. Benefit of combining local treatment and systemic therapy for stage IV NSCLC: Results from the National Cancer Database. Journal Of Clinical Oncology 2019, 37: 8545-8545. DOI: 10.1200/jco.2019.37.15_suppl.8545.Peer-Reviewed Original ResearchNon-small cell lung cancerNational Cancer DatabaseStage IV non-small cell lung cancerStage IV NSCLC patientsSystemic therapyOverall survivalSurgical resectionPatient demographicsNSCLC patientsCancer DatabaseMultivariable Cox proportional hazards modelsSquamous cell carcinoma patientsPropensity scoreMultivariable logistic regression modelCox proportional hazards modelSuperior overall survivalCell carcinoma patientsCell lung cancerLung cancer treatmentProportional hazards modelLogistic regression modelsLimited nodalTA patientsMetastatic diseaseMultivariable adjustmentRefining the role of adjuvant chemotherapy in stage IB and IIA NSCLC.
Pathak R, Hoag J, Goldberg S, Monsalve A, Resio B, Boffa D. Refining the role of adjuvant chemotherapy in stage IB and IIA NSCLC. Journal Of Clinical Oncology 2019, 37: 8519-8519. DOI: 10.1200/jco.2019.37.15_suppl.8519.Peer-Reviewed Original ResearchNon-small cell lung cancerNational Cancer Data BaseHigh-risk featuresIIA non-small cell lung cancerAdjuvant chemotherapyStage IBGuideline recommendationsMultivariable Cox proportional hazards regressionBenefit of ACTMulti-agent adjuvant chemotherapyRole of ACSingle-agent adjuvant chemotherapyUse of ACCox proportional hazards regressionStage IB patientsCell lung cancerProportional hazards regressionImmortal time biasNon-academic centersPT2N0 patientsT2a patientsT2b patientsNSCLC patientsSurvival benefitAC patients
2018
Variable impact of prior cancer history on the survival of lung cancer patients
Monsalve AF, Hoag JR, Resio BJ, Chiu AS, Brown LB, Detterbeck FC, Blasberg JD, Boffa DJ. Variable impact of prior cancer history on the survival of lung cancer patients. Lung Cancer 2018, 127: 130-137. PMID: 30642541, DOI: 10.1016/j.lungcan.2018.11.040.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerPrior cancer historyNational Cancer DatabaseCancer historyOverall survivalNSCLC patientsMultivariable Cox proportional hazards regression modelsTreatment approachesCox proportional hazards regression modelProportional hazards regression modelsKaplan-Meier survival curvesNSCLC patient survivalCell lung cancerHazards regression modelsLung cancer patientsPrior cancerPrior malignancyNSCLC survivalPatient survivalCancer patientsLung cancerCancer DatabasePatient's potentialPrior historyPatients